CD8+ TILs and Breast Cancer: Identifying New Opportunities for Immunotherapeutic Intervention

In this webinar, Dr. Egelston discusses recent efforts to isolate and characterize phenotypically and functionally exhausted CD8+ TILs from a subset of breast tumors.
Publish Date: August 30, 2019 Views: 0

Contact STEMCELL Technologies

Our Customer Service, Sales, and Product and Scientific Support departments in North America are available between 6 am and 5 pm Pacific Time (9 am and 8 pm Eastern Time). One of our representatives will be happy to help you by telephone or email. Please complete the form to contact us by email. A representative will get back to you shortly.
  •  

StemCell Technologies Inc. and affiliates ("STEMCELL Technologies") does not share your email address with third parties. StemCell Technologies Inc. will use your email address to confirm your identity and send you newsletters, transaction-related emails, promotional and customer service emails in accordance with our privacy policy. You can change your email preferences at any time.